Advertisement


Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Matthew Seymour, MD: A Clinical Trialist’s Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Peter Clark, MA, MD, FRCP: A Payer Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Advertisement